| Fibrinolytic therapy (n = 1786) | Primary PCI (n = 2173) | |
| Demographics | ||
| Median age, years (IQR) | 63 (53 to 73) | 61 (53 to 72) |
| Women, % | 26 | 24 |
| Clinical characteristics, % | ||
| Prior myocardial infarction | 17 | 14 |
| Prior heart failure | 4.2 | 2.0 |
| Prior coronary intervention | 5.6 | 9.5 |
| Prior bypass surgery | 3.6 | 2.8 |
| Smoker (current or former) | 64 | 64 |
| Diabetes | 17 | 18 |
| Hypertension | 45 | 48 |
| Hyperlipidaemia | 35 | 38 |
| Clinical presentation | ||
| Median pulse, beats per min (IQR) | 74 (62 to 87) | 75 (64 to 88) |
| Median systolic blood pressure, mm Hg (IQR) | 138 (120 to 157) | 130 (114 to 151) |
| Median diastolic blood pressure, mm Hg (IQR) | 80 (70 to 92) | 80 (69 to 90) |
| Cardiac arrest, % | 4.1 | 4.7 |
| Killip class II, % | 11 | 11 |
| Killip class III, % | 2.3 | 1.8 |
| Killip class IV, % | 1.0 | 2.9 |
| ST-segment deviation on electrocardiogram, % | 99 | 99 |
| Positive cardiac biomarkers, % | 38 | 49 |
| Median serum creatinine, mg/dL (IQR) | 1.0 (0.9 to 1.2) | 1.0 (0.9 to 1.2) |
| Median time delay, min (IQR) | ||
| From symptom onset to presentation | 104 (60 to 108) | 120 (70 to 186) |
| From door to treatment* | 35 (20 to 62) | 78 (47 to 120) |
*For fibrinolytic therapy, door-to-needle time; for primary PCI, door-to-balloon time.
IQR, interquartile range; PCI, percutaneous coronary intervention.